Delving into the Latest Updates on Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret As with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

αvβ3 x αvβ5 x αvβ6	1

This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors. The research is planned as a two-step study (Phase Ia and phase Ib) and accelerated titration design (ATD) is used.

Start Date13 Dec 2021

Sponsor / Collaborator

Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret As

100 Clinical Results associated with Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret As

Login to view more data

0 Patents (Medical) associated with Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret As

Login to view more data

100 Deals associated with Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret As

Login to view more data

100 Translational Medicine associated with Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret As

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data